Status:
COMPLETED
Cardiac Autonomic Regulation Enhancement Through Exercise Trial
Lead Sponsor:
The Miriam Hospital
Conditions:
Cardiovascular Disease, Arrhythmias
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The current research study proposes to examine participants with implantable cardioverter defibrillators (ICD) who are randomly assigned to either an exercise training program intervention or a heart ...
Eligibility Criteria
Inclusion
- adult ICD patients (≥ 18 years of age)
- received an ICD for secondary prevention, cardiac diagnosis of: ventricular fibrillation, OR ventricular tachycardia, OR cardiac arrest, OR syncope with ventricular tachycardia inducible by programmed stimulation (EPS), AND
- either diagnosed coronary artery disease AND/OR prior myocardial infarction, or non-ischemic dilated cardiomyopathy
- meet functional NYHA Class I or II heart failure or angina symptoms
- ICD patients need to be sedentary, defined as not engaging in structured exercise more than once weekly, or an accumulation of less than 60 minutes of moderate intensity aerobic activity over the course of the week, for the past 3 months.
- deemed medically stable by their cardiologist and have received approval by their cardiologist to engage in an exercise program
- Stable (unchanged) cardiac and psychopharmacologic medications in the 3 months prior to study enrollment
- Able to read and write English
- able to commit to the 3-month exercise/heart healthy program attending 3 times per week (36 sessions)
- able to commit to the 3 assessments (pre, post-treatment, 3-month follow-up; 6-month duration)
Exclusion
- Patients who meet functional NYHA Class III or IV heart failure or angina symptoms
- sinus node dysfunction that requires atrial pacing
- atrial fibrillation
- bi-ventricular ICD
- are pacemaker-dependent
- diagnosis of Brugada's Syndrome
- diagnosis of arrhythmogenic right ventricular dysplasia
- complex congenital heart disease
- orthopedic restrictions, limitations, or disabilities that would jeopardize the patient's safety during exercise or form completing the treadmill stress test
- Neurocognitive or cognitive impairments that will result in nonadherence (based on clinical evaluation)
- Unstable angina
- resting systolic blood pressure \>180mmHg or resting diastolic blood pressure \>110mm Hg will be evaluated on a case-by-case basis
- orthostatic blood pressure drop of \>20mm Hg with symptoms
- critical aortic stenosis (peak systolic pressure gradient \>50mm Hg with aortic valve orifice area \<0.75cm2 in average size adult)
- acute systemic illness or fever
- uncontrolled atrial or ventricular arrhythmias
- uncontrolled sinus tachycardia (\>120 beats/min)
- uncompensated CHF
- 3rd degree AV block (without pacemaker)
- active pericarditis or myocarditis
- recent embolism; thrombophlebitis
- resting ST segment displacement (\>2mm)
- uncontrolled diabetes (resting blood glucose \>400mg/dl)
- metabolic problems, such as acute, hypo or hyperkalemia, hypovolemia
- recent strongly positive exercise test as achieved by: significant decrease in systolic blood pressure with increasing workload, OR early onset, horizontal or downsloping ST segment depression (4mm), OR prolonged electrocardiogram (ECG) changes during recovery
- hypertrophic obstructive cardiomyopathy
- severe pulmonary hypertension
- patients who do not pass the exercise stress test
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00845091
Start Date
February 1 2009
End Date
July 1 2011
Last Update
January 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Miriam Hospital Centers for Behavioral and Preventive Medicine
Providence, Rhode Island, United States, 02903